88,328 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Purchased by AQR Capital Management LLC

AQR Capital Management LLC bought a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 88,328 shares of the company’s stock, valued at approximately $564,000. AQR Capital Management LLC owned 0.15% of Health Catalyst at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of HCAT. Nisa Investment Advisors LLC raised its holdings in shares of Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the period. Perfromance Wealth Partners LLC bought a new stake in Health Catalyst in the second quarter valued at about $64,000. EntryPoint Capital LLC bought a new position in shares of Health Catalyst during the first quarter valued at approximately $98,000. Virtus Investment Advisers Inc. bought a new position in shares of Health Catalyst during the first quarter valued at approximately $115,000. Finally, XTX Topco Ltd boosted its position in shares of Health Catalyst by 48.2% during the second quarter. XTX Topco Ltd now owns 28,420 shares of the company’s stock worth $182,000 after buying an additional 9,248 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on HCAT shares. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Piper Sandler decreased their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. JPMorgan Chase & Co. upped their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Evercore ISI increased their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Stephens dropped their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus target price of $11.58.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares in the company, valued at $1,062,018.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares in the company, valued at $1,062,018.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,072 shares of company stock valued at $247,611. Company insiders own 2.70% of the company’s stock.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $8.23 on Tuesday. The company has a market capitalization of $485.86 million, a price-to-earnings ratio of -4.45 and a beta of 1.32. The company has a 50-day simple moving average of $7.53 and a 200 day simple moving average of $6.90. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. During the same quarter in the prior year, the firm posted ($0.21) EPS. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. Sell-side analysts forecast that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.